Guard Dog Brand Development Receives Three Silver Davey Awards in the Corporate Identity Category in the 5th Annual International Davey Awards for 2009
NEW YORK–(BUSINESS WIRE)– The 5th Annual International Davey Awards has recognized Guard Dog Brand Development (www.GuardDogBD.com) with a Silver Davey Award for the Corporate Identity Program it developed for the Multiple Myeloma Research Foundation (www.themmrf.org) as well as with two Silver Davey Awards for Infinity Pharmaceutical’s 2009 Corporate Exhibit Booth.
The 2009 Davey Awards featured an incredible pool of over 4000 entries from the best boutique firms in the world; being honored with three Silver Davey Awards is truly a great accomplishment. It is a testament to the award-winning work that GDBD does.
“Having a healthy brand identity is so much more than just a logo or a look and feel. It’s about uncovering the balance between a brand’s emotional benefits and functional assets, and understanding how best to represent the corporate brand, particularly for leading organizations and companies such as the MMRF and Infinity Pharmaceuticals,” said Camille DeSantis and Maria Casini, co-founders and co-presidents of GDBD. “We are thrilled that the corporate identities we developed with the MMRF and with Infinity Pharmaceuticals have been honored with these three prestigious awards.”
About Guard Dog Brand Development® (GDBD):
GDBD is a novel brand development company specializing in creating and fiercely protecting corporate, product, and science identities. Please visit www.GuardDogBD.com for more information.
About the Multiple Myeloma Research Foundation:
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world’s number-one private funder of multiple myeloma research, the MMRF has raised more than $130 million since its inception to fund more than 120 laboratories worldwide. An outstanding 93 percent of funds raised go toward research and related programming. The MMRF has supported 40 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 20 clinical trials through its sister organization, the Multiple Myeloma Research Consortium (MMRC). For more information about the MMRF, visit www.themmrf.org.
About Infinity Pharmaceuticals, Inc.:
Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity’s two most advanced programs in Hsp90 chaperone inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company’s website at http://www.infi.com.